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Summary Cytogenetic findings of our 30 previously reported and eight new patients with malignant pleural
mesothelioma were summarised and correlated with asbestos fibre burden in lung tissue and survival.
Successful cytogenetic analyses were performed on cells obtained from the tumours and/or pleural effusions of
34 of the 38 patients. Clonal chromosomal abnormalities were detected in 25 patients, 19 of them studied
before treatment. Nine patients, seven of them studied before treatment, had normal karyotypes and/or
non-clonal chromosomal abnormalities. Most of the karyotypic findings in the patients with clonal abnor-
malities were complex and heterogeneous, and no chromosome aberration specific to mesothelioma could be
demonstrated. The following numerical abnormalities in decreasing order of frequency were preferentially
present in karyotypic changes: - 22, + 7, - 1, - 3, - 9, + 11 and - 14 (-/ + denoting partial or total loss
or gain). Translocations and deletions involving a breakpoint at Ipl -p22 were the most frequent structural
aberrations. Statistically significant correlations were found between high content of asbestos fibres in lung
tissue and partial or total losses of chromosomes 1 and 4, and a breakpoint at lplI-p22 (P = 0.0001,
P = 0.003, P = 0.009, respectively). The number of copies of chromosome 7 short arms was inversely
correlated with survival (P = 0.02). In this study no diagnostic cytogenetic markers of mesothelioma were
found, instead the copy number of chromosome 7 short arms turned out to be a possible prognostic factor in
malignant mesothelioma.
The incidence of malignant mesothelioma has risen with the
increased use of asbestos in industry (Antman, 1980; Browne,
1986). Mesothelioma is characterised by a long latency
period, diagnosis at an advanced stage, resistance to therapy,
and short survival (Antman, 1980). The histological, and
especially cytological, distinction between mesothelioma and
adenocarcinoma metastatic to the pleura can be difficult
(Battifora & Kopinski, 1985; Burns et al., 1985). Specific
chromosomal abnormalities serve as diagnostic markers and/
or prognostic factors in several malignancies (Heim & Mitel-
man, 1987). Reports on cytogenetic analyses of mesothelioma
have been sparse and no anomaly specific to mesothelioma
has been found so far (Ayraud, 1975; Mark, 1978; Wake et
al., 1981; Gibas et al., 1986; Stenman et al., 1986; Bello et al.,
1987; Popescu et al., 1988; Tiainen et al., 1988; Hagemeijer et
al., 1988). In this report a summary of the chromosomal
analyses of our 30 previously reported (Tiainen et al., 1988)
and eight new malignant pleural mesotheliomas is presented,
and the cytogenetic findings are evaluated for their correla-
tions with concentrations of asbestos fibres in lung tissue and
survival.
Materials and methods
Clinical material
Seventy-five specimens from tumours and/or pleural effusions
from 38 patients with malignant pleural mesothelioma diag-
nosed in the catchment area of the Helsinki University Cent-
ral Hospital between 1984 and 1987 were cytogenetically
studied. The cytogenetic data and patient characteristics of
patients nos 1-30 have been previously reported (Tiainen et
al., 1988). The diagnosis and histological subtyping of meso-
thelioma were confirmed by two different pathology panels,
by both the Finnish National Mesothelioma Pathology Panel
and the corresponding panel of the Lung Cancer Cooperative
Group of the European Organisation for Research and Treat-
ment of Cancer. All available methods to exclude other
primaries were applied (Corson, 1987). Thirty of the patients
were male, and the median age at diagnosis was 59 (range
39-83) years. The histological subtype was epithelial in 19
patients, mixed in 16, and fibromatous in 2. In one patient
material for cytological diagnosis only was available not
allowing subtyping. Most (25) of the patients had clinical
stage II A disease.
Asbestos exposure was evaluated in 16 patients by deter-
mination of the content of asbestos fibres in samples of dried
lung tissue. Eleven patients had more than 5 million asbestos
fibres per gram in their lung tissue (range 5.5-370 million
fibres per gram dry tissue; Table I). They had been exposed
to asbestos in shipyards, construction and maintenance work.
Five patients had less than 5 million fibres per gram in lung
tissue (range 0.1-3.1 million fibres per gram dry tissue; Table
I). They had been exposed in various occupations in con-
struction industry, electrical installations, powerplant and
transport trades. The main fibre types found in both groups
were crocidolite, amosite and anthophyllite asbestos. The
latency period between the exposure and the diagnosis of
mesothelioma was more than 20 years and the work where
the exposure was considered to have taken place had con-
tinued for typically several years (Tuomi et al., 1989).
The patients were treated with multimodality therapy con-
sisting of debulking surgery, chemotherapy and hemithorax
irradiation. Chemotherapy comprised either single agent mit-
oxantrone, single agent epirubicin or combination chemo-
therapy with cyclophosphamide, vincristin, doxorubicin and
dakarbazin (CYVADIC). Three different time-dose-fraction-
ation programmes of hemithorax irradiation were applied
(Holsti & Mattson, 1988; Mattson et al., 1989). More de-
tailed patient characteristics, individual therapies and survival
data are presented in Table I.
Cytogenetic studies
Cells for conventional cytogenetic analyses (method described
previously, Tiainen et al., 1988) were obtained from speci-
mens of 37 tumours and 38 pleural effusions. Several speci-
mens were received for most of the patients. Tumour tissue
samples were available from 32 patients and pleural effusion
specimens from 27. Both specimens were received from 21
patients. Samples were obtained before treatment from 32
patients. Twenty metaphases or more were usually karyo-
typed for each specimen using the G-banding technique and,
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Table I Clinical characteristics and cytogenetic findings in 38 patients with malignant pleural mesothelioma.
Asbestos Hemithorax Survival,
Patient Sex/age at Histological Clinical fibre Chemotherapy irradiation, (monthsfrom Cytogenetic
no. diagnosis subtype stage contentbc cycles total dose (GY) diagnosis)d findings
I M/47 Epithelial II B 26,cr./am./an. 2 x MTX - 8 MAKA
2 M/44 Epithelial III A ND 6 x CYVADIC 55 31 NCA (t)
3 F/42 Epithelial II A ND 5 x MTX 55 49 MAKA (t)
4 M/71 Epithelial II A ND - 55 26 NCA
5 M/51 Epithelial III B ND 1 x MTX - 3 MAKA (t)
6 M/75 Epithelial II A ND - 55 3 MAKA, SIKA
7 F/43 Epithelial II A ND 6 x MTX 70 37+ NR
8 M/60 Mixed II A ND 4 x 4-epi 35 + 36 6 MAKA, SIKA
9 M/72 Mixed I 21, cr./am. 6 x MTX 70 19 MAKA
10 M/58 Epithelial 11 A ND - 55 12 MAKA
11 M/73 Epithelial I ND - 55 11 NCA (t)
12 M/55 Mixed II A I I,cr./an. 3 x 4-epi 35 + 36 13 MAKA
13 M/59 Epithelial II A 370, cr./an. 6 x MTX 70 27 MAKA
14 M/52 Mixed I 3.1,cr./am./an. 4 x MTX 70 14 MAKA (t)
15 M/66 Unknowna 11 B ND 2 x MTX - 2 NCA
16 F/83 Fibromatous I ND - - 25 SIKA
17 F/66 Epithelial II A ND 55 4 MAKA
18 M/67 Mixed II A ND 1 x CYVADIC - 4 MAKA
19 F/55 Fibromatous I ND - 55 45+ Normal
20 M/39 Mixed II A ND 6 x 4-epi 35 + 36 20 MAKA (t)
21 M/41 Mixed II A 11, cr./am. 5 x MTX - 18 MAKA
22 F/71 Epithelial II A ND - 55 7 NCA
23 M/52 Mixed 1 13, cr./am. 6 x MTX 70 14 MAKA (t)
24 M/51 Epithelial 11 A ND - - 5 Normal
25 M/71 Mixed II A 17, cr./am./an. 5 x MTX 6 MAKA
26 M/59 Mixed II A 5.5,cr./am./an. 2 x MTX - 3 MAKA
27 M/69 Epithelial II A ND 1 x PLAT 55 13 MAKA (t)
28 M/73 Epithelial 11 A ND - 55 14 NR
29 M/59 Mixed II A ND 2 x MTX - 4 MAKA
30 F/60 Epithelial 11 A ND 4 x MTX 70 20 NR
31 M/60 Mixed III B ND 3 x 4-epi 35 + 36 18 SIKA
32 M/54 Epithelial II A 160, cr./am. - 35 + 36 6 MAKA
33 M/46 Mixed II A 34,cr./am./an. 3 x 4-epi 35 + 36 14 MAKA
34 M/65 Mixed 11 A 0.8,- 6 x 4-epi 35 + 36 19+ NCA
35 M/71 Epithelial II A 1.2, cr./am./an. - - 17 MAKA
36 M/42 Mixed IV 4.l,cr./am. - 2 SIKA
37 M/54 Mixed II B 6.2,an. - - 6 NR
38 F/57 Epithelial II A 0.l,an. Bleo 35 + 36 11 + NCA
Clinicalstage: I, ipsilateral pleura andlungonly; IIA, ipsilateral chestwall, mediastinal orpericardial invasion; IIB,extension tocontralaterallungor
pleura; III, extrathoracic extension, A, nodes outside chest; B, extension through diaphragm to peritoneum; IV, distant metastases.
Chemotherapy: MTX, mitoxantrone i.v. (intravenous), 14 mg m 2 q 3 week; CYVADIC, cyclophosphamide 500mg m 2 day 1, vincristin 1 mg days
I + 5, doxorubicin 40 mg m 2 day 1, dakarbatzin 200 mg days 1 -5, q 3 week, i.v.; 4-epi, 4-epidoxorubicin i.v., 110-130 mg m 2 q 3 week; Bleo,
bleomycin i.p. (intrapleural), 40 mg; PLAT, cisplatinum, i.v., 90 mg m-2.
Cytogeneticfindings: MAKA, major karyotype abnormality; NCA, nonclonal abnormality; NR, no result; SIKA, simple karyotype abnormality, (t),
result after therapy.
aInsufficient material for subtyping, clinical findings, CT scan findings and cytology were thediagnostic criteria. b Xmillion asbestosfibres per gramof
dried lung tissue; ND, not done. cType of asbestos fibres: cr./am., crocidolite, amosite or both; an, anthophyllite; -, not identified.d +, alive.
if required, the C- and R-banding techniques also. Chrom-
osomal abnormalities were considered as clonal if they app-
eared in at least two cells, except chromosomal losses, which
had to be in at least three cells. The constitutional karyotype
of every patient was confirmed as being normal by cyto-
genetic analysis of cells from peripheral blood.
Statistical analyses
Statistical analyses were performed with the BMDP statistical
software package (Dixon, 1985). Differences between groups
were analysed with the likelihood ratio X2 test or analysis of
variance. Survival analyses were calculated by the product
limit method, and the groups were compared by the Man-
tel-Cox test.
Results
Success rates in cytogenetic analyses ofdifferent specimens
Metaphases for karyotypic analyses were obtained from 56 of
the 75 specimens, 32 of 38 (84%) specimens from pleural
effusions and 24 of 37 (65%) specimens from tumours.
Thirty-seven per cent of the specimens from pleural effusions
yielded metaphases with clonal chromosomal abnormalities
and 47% yielded metaphases with normal karyotypes and/or
non-clonal abnormalities. The corresponding figures for spec-
imens from tumours were 51% and 14% respectively.
Cytogeneticfindings in samples of34 patients
Successful chromosomal studies were performed on speci-
mens from 34 patients. Clonal major karyotype abnormalities
and/or simple karyotype abnormalities were detected in tu-
mour cells from 25 patients (Table I, 19 of them before
treatment). In most of the patients there were also cells with
normal karyotype and cells with nonclonal abnormalities in
the same specimen. In two patients only a few normal meta-
phases were found (Table I, both before treatment). The
remaining seven patients had a mixture of normal and non-
clonal metaphases (Table I, five before treatment). Detailed
results of the chromosomal analyses of patients nos 1-30
have been previously reported (Tiainen et al., 1988). The
karyotypic findings in the samples of patients nos 31-38 (all
before treatment) and in a new specimen (metastasis, after
treatment) of patient no. 20 are presented in Table II.
A stemline with a pseudodiploid or near diploid chrom-
osome number was detected in 21 of the patients with clonal
abnormalities. Thirteen of them also had polyploid forms of620 M. TIAINEN et al.
Table II Karyotypic findings in mesothelioma patients nos 20 and 31-38
Karyotype
MAKA Source Culture
Case of time No. of Description ofthe
no. sample (days) cells Gains Losses marker chromosomes
20 T 2-7 11 37-42,MAKAa 2,4,9,9,10, mar I der(l)t(l;?)(p13;?)
I I (53)69-82,MAKA
102,MAKA
154,MAKA
12,13,14,15,
16,17
2 Ip-
3 del(l)(q?12)
4 2q+
S del(3)(p?13p?21)
6 der(5)t(5;?)(p?13;?)
7 der(6)t(6;?)(q12;?)
8 der(7)t(7;?)(p?2 1;?)
9 der(8)t(8;?)(pl?;?)
10 der(8)t(8;?)(p1?;?)
I1I der(l l)t(ll;?)(pl I;?)
12 der(l l)t(X;l l)(ql3;p13)
13 ?del(22)(qI 1.2)
14 r(?)
+ 5-8 unidentified mar
31 T 22-43 10
3
3
10
11
32 T 0-6 13
2
4
1
33 T 22 7
8
18
34 T 35-38 9
41
35 T 9-15 20
6
5
7
2
44-46,XY,t(9;1 1)(q22;p15)
45 -46,XY,+21,t(14q;17q)
46,XY,t(5;13)(pl5;q12)
46,XY
40-46,NCA
35-43,MAKA'
50-52,MAKA
75-86,MAKA
46,XY
69-89,MAKA
41 -47,NCA
46,XY
3,4,9,9,10,
10,13,13,14,
15,17,18,19
*1,1,3,4,4,
5,6,6,8,8,
9,9,10,10,
13,13,14,14,
15,15,16,16,
17,17,18
41 -47,NCA
46,XY
(33,35)42-47,MAKA
(60)89-93,MAKA
39-46,NCA
46,XY
92,XXYY
mar
mar
I der(l)t(l;7)(p13;q 11.2)
2 der(2)t(2;?)(pl 1;?)
3 del(3)(p12p21)
4 der(5)?t(5;?)(q15 -31;?)
5 der(8)t(1;8;?)(8qter-
8p23::?::Iq21-qter)
6 8p?-
7 i(llq)
8 der(l 1)?t(l 1;?)(q21;?)
9 r(?)
+ 8-9 unidentified mar
I der(l)?t(l;2)(q25;p25)
2 der(2)?t(l;2)(q25;p25)
3 del(11)(q23)
(mar 1-3 two copies per
cell)
+ 9-24 unidentified mar
mar I der(2)t(2;?)(p23;?)
2 del(3)(p?13p?21)
3 3p-
4 der(3)t(3;?)(q?13;?)
5 del(6)(q11)
6 t(22;?)(q?13;?)
+ 1-2 unidentified mar
36 T 7-20 24 47 -50,XY,+X,+Y,+i(5p), +i(5p)c
8 93-l00,XXYY,+X,+X,+Y,+Y,+i(5p),
+i(5p), +i(5p), +i(5p)
13 46,XY
PL 0-17 NR
37 T 0-15
38 T 0-38
PL 31-34
NR
NR
11 41 -91,NCA
17 46;XX
T, tumour; PL,pleuraleffusion; MAKA,majorkaryotypeabnormality; clonal abnormalities present in MAKA arelistedbeside; NCA, nonclonal
abnormality; NR, no result; *compared with normal tetraploid karyotype.
aFigure la; bFigure Ib; cFigure 2.
the stemline. Four patients showed a stemline with a chrom-
osome number in the triploid-tetraploid range. The overall
pattern of the cytogenetic findings in the 25 mesotheliomas
with clonal abnormalities was complex. Gain and loss of
chromosomal material, unbalanced translocations,
unidentified markers and clonal evolution were common
findings (Figure 1). Many unidentified markers were present
in tumour cells from several patients so the interpretation of
true chromosomal losses was difficult. Three patients had
quite simple karyotypic changes: 48,XX, +5,+7 (patient no.
16), 46,XY,t(9;1 1)/+21,t(14q; I7q)/t(5;13) (three different
clones, patient no. 31) and 50,XY, +X, +Y, +i(5p), +i(5p)
(stemline of patient no. 36, Figure 2). Clonal numerical
chromosome changes including partial or total chromosomal
gains and losses are summarised in Figure 3. Distribution of
breakpoints of the clonal structural changes on different
chromosomes is demonstrated in Figure 4.CHROMOSOMAL ABNORMALITIES IN MESOTHELIOMA 621
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Figure 1 G-banded karyotypes including complex chromosomal changes of tumour cells from patient nos 20 (a) and 32 (b). A
description of the marker chromosomes is given in Table II. The karyotype from patient no. 32 includes, e.g., partial loss of
chromosome 1, a breakpoint at 1pl3 and loss of chromosome 4. These abnormalities were associated with high concentration of
asbestos fibres in lung tissue, which in this patient was 160 million fibres per gram of dried tissue.
Consistent chromosomal abnormalities
No chromosomal abnormality specific to mesothelioma was
detected in this study. However, certain chromosomes were
preferentially involved in karyotypic changes. The most fre-
quent chromosomal loss, partial or total monosomy 22, was
detected in 14 of 25 patients (56%). Material from chrom-
osomes I and 3 was missing in 12 patients (48%). In eight
patients the short arm of chromosome 1 was lost, and seven
of them had an overlapping area in lp22-lp36.3. Deletions
of the short arm ofchromosome 3 occurred in seven patients,
and all had an overlapping area in 3pl3-p2l. Partial or total
loss of chromosomes 9, 14, 15 and 4 was detected in 11, 11,
10 and 9 patients respectively.
Partial or total polysomy 7 was the most frequent chrom-
osomal gain in the tumour cells of the 25 patients, it was
detected in 13 patients (52%). Partial polysomy appeared
especially in the form of extra copies of the short arm of
chromosome 7 (isochromosomes of 7p were detected in three
patients and an additional translocation chromosome involv-
ing 7p material in one patient). Gain of chromosome 11 was
seen in 11 patients, gain of chromosome 5 in eight patients
(two of them having isochromosomes (5p)) and gain of
chromosome 12 in seven patients. The involvement of the
above abnormalities in the karyotypic changes in the 25
mesotheliomas is presented in Table III.
Most breakpoints occurred in chromosomes 1, 3, 2, 9, 11
and 7, in decreasing order of frequency (Figure 4). Breakage
in chromosomal bands plp, lpll3, lp22, lq21, 3pl3, 3p2l,
6ql2, 7ql 1.2, 21q22 and 22ql 1.2 occurred in more than two
patients. There was a cluster of breakpoints in regions
lpl 1-p22 (10 patients, Table III), lql2-q25 (8 patients),
3pl 1-21 (6 patients) and 7ql 1.2 (4 patients).
The co-existence ofdifferent chromosomal abnormalities
The correlations between the different chromosomal altera-
tions are demonstrated in Figure 5. Two groups can be
separated: a group of chromosomal gains accompanying par-
tial or total polysomy 7, and a group of chromosomal losses
accompanying partial or total loss of chromosome 3 or a
breakpoint at lpl -p22. In the first group partial or total
polysomy 7 tended to occur together with polysomies 5, 11
and 12 (for each, P<0.01). Six of the seven cases that had
polysomy 12 had also gained chromosome 11 (P<0.001). In
the second group, the most statistically significant correla-
tions (P<0.0001) were detected between a breakpoint at
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Figure 2 a, A G-banded karyotype 50,XY, +X, +Y, +i(5p), +i(5p) from patient no. 36. b, A partial R-banded karyotype of
B-group chromosomes and isochromosomes (5p).
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Figure 3 Chromosomal gain (left) and loss (right) of the 25 cases with clonal chromosomal abnormalities. Single or combined
lines represent one patient. Intact lines are from patients nos 1, 3, 5, 6, 8, 9, 10, 12, 13, 14, 16, 17, 18, 21, 23, 25, 26, 27 and 29
(Tiainen et al., 1988); dotted lines are from patients nos 20, 31, 32, 33, 35 and 36.
lpl I -p22 and -14; lpl I -p22 and -15; -1 and -4; -1
and -9; -3 and del(3p); -3 and -9; -3 and -22; and
between -4 and -9 (- denoting partial or total loss). No
significant associations could be demonstrated between 'chro-
mosome 7 group abnormalities' and 'chromosome I and 3
group abnormalities'. On the contrary, there was a significant
negative correlation between chromosome 5 and chromosome
3 abnormalities and between chromosome 12 and chromo-
some 3 abnormalities (P<0.01).
Correlations ofcytogeneticfindings, the content ofasbestos
fibres in lung tissue and survival
The following cytogenetic findings were evaluated for correla-
tions with the quantitative data of asbestos fibre content in
the corresponding lung tissue and survival: presence of clonal
chromosomal abnormalities, non-clonal abnormalities and
normal karyotypes (Table I), and the presence of each chro-
mosomal abnormality presented in Table III. As partial poly-
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Figure 4 Distribution of chromosomal breakpoints of cases with
clonal abnormalities. Each star and each line (patients nos 1, 3, 5,
6, 8, 9, 10, 12, 13, 14, 16, 17, 18, 21, 23, 25, 26, 27 and 29
(Tiainen et al., 1988)) and each dot and each dotted line (patients
nos 20, 31, 32, 33, 35 and 36) represent one breakpoint (lines
indicate breakpoints that could not be determined exactly).
-1%.%*' ~ -15
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Figure 5 Co-existence of different chromosome abnormalities.
-/+, partial or total chromosome loss or gain; del3p, deletion of
the p-arm of chromosome 3; bplpl -p22, breakpoint at
Ipl I -p22.
somy 7 appeared especially in the form of extra copies of the
p-arms, the significance of polysomy 7 was evaluated by the
number of additional copies of 7p.
Partial or total losses of chromosomes 1 and 4, and chro-
mosomal rearrangements involving a breakpoint at
lpll-p22 were consistently accompanied by asbestos fibre
concentrations greater than 5 million fibres per gram of dried
lung tissue (P = 0.0001, P = 0.003 and P = 0.009 respectively,
Figure lb). In addition, the number ofcopies of chromosome
7 short arms in the tumour cells correlated inversely with
survival (P = 0.02). Patients with monosomy 7p or with a
normal copy number of 7p:s survived longer than those with
1-4 additional 7p:s, and the more copies of chromosome 7
p-arms that were present in the tumour cells the worse was
the prognosis (Figure 6).
Table III Consistent chromosome changes in 25 mesotheliomas with clonal abnormalities
Chromosome abnormalities
Patient Breakpoint
no. la Ipl -p22 _3a del(3p) 4a +5b +7b _ga +Ub +12 14a 15a 22a
I + + - + - + + + + + +
3 + + + + + - + - + + +
S - + - . . . . . .- + + +
6 - + - + +(1) + - + -
8 - - - + +(3) + + - - -
9 + - - +(1) + + _ _ _
10 - + + +(3) + - + + +
12 + + + + - + - + + +
13 + + + + - + - + - _
14 - - - +(1) - - - +
16 - - - + +(1) - - - -
17 - - + +(2) + + - - - +
18 + - _ + +(1) _ _ +
20 + + + + + - + + + + +
21 + - + + +(2) + - - - +
23 + - - + + +(2) + + + - + -
25 + + + + + - + - + - +
26 - - + + - - +(1) + + - + - +
27 + - + + - - - - - +
29 - - - + +(4) + + - + -
31 _ _ _ _ +
- _
32 + + + + + - + + - + + -
33 - - - + +(1) + + - - -
35 - - + +. . . . . .- - - +
36 - - - - - + - - - - - -
Total+ 12 10 12 7 9 8 13 11 11 7 11 10 14
aPartial or total monosomy; bpartial or total polysomy; number of extra copies of 7p in parentheses.
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Figure 6 Correlation between the number of copies of chrom-
osome 7 p-arms and survival (P = 0.02). a, Four extra 7p:s
(patient no. 29); b, three extra 7p:s (patients nos 8 and 10); c, two
extra 7p:s (patients nos 17, 21 and 23); d, one extra 7p (patients
nos 6, 9, 14, 16, 18, 26 and 33); e, normal number of 7p:s
(patients nos 1, 2, 4, 5, 11, 12, 15, 19, 20, 22, 24, 25, 27, 31, 34,
35, 36 and 38); and f, loss of a copy of 7p (patients nos 3, 13 and
32).
Discussion
In the present study the cytogenetic data were obtained
mainly from specimens from the primary tumours received
before treatment of 34 patients with malignant pleural meso-
thelioma. The histological diagnosis and subtyping were
based on the same specimens. Karyotypic analyses of the 25
mesotheliomas with clonal chromosome abnormalities revea-
led numerous and often complex chromosomal changes, and
heterogeneity between different cases and within a single case.
The following partial or total chromosomal gains (+) and
losses (-) were found most frequently: - 22; +7, - 1, - 3,
-9, +11, -14, -15, -4, +5 and +12 (in decreasing order
of frequency). Clustering of breakpoints was detected in
regions lpll-22, 1ql2-q25, 3pll-21 and 7ql1.2, of which
Ipl- p22 was the most common. These findings are partly
confirmed by other studies. Deletions of the short arm of
chromosome 3 have been the most frequent abnormalities in
the 25 cases reported by Ayraud (1975), Mark (1978), Wake
et al. (1981), Gibas et al. (1986), Stenman et al. (1986), Bello
et al. (1987) and Popescu et al. (1988). Structural abnor-
malities involving a breakpoint at Ip Il -p22, and both struc-
tural and numerical changes involving chromosome 7 have
also been detected commonly in those studies. In a recent
study of chromosomal changes in 38 mesotheliomas
(Hagemeijer et al., 1988) (abnormal clones in 26 cases) con-
sistent involvement of chromosomes 1, 3, 6, 9 and 13 in
structural changes and chromosomes 4 and 22 in losses and
chromosomes 5, 7 and 20 in gains was found.
Our analysis of the co-existence of different chromosome
abnormalities showed that two groups could be separated:
chromosome 5, 7, 11 and 12 gains in the first group, and
chromosome 1, 3, 4, 9, 14, 15 and 22 losses and a breakpoint
at lpll-p22 in the second. Such correlations at the chrom-
osomal level may reflect correlations at the molecular level:
co-operation of different oncogenes or growth factor genes,
loss of suppressor genes, gene dosage effect or gene position
effect. It is interesting that NRAS and two NRAS-like
oncogenes are located in chromosomal regions frequently
involved in chromosomal changes in mesotheliomas: Ip13
and/or lp22, 9p and 22 (Human Gene Mapping 9.5, 1988).
The possible role of NRAS in mesothelioma is not yet
known. Several oncogenes, like ERBB (EGFR), which has
been shown to be amplified in some tumours (Hollstein et at.,
1988), and the multiple drug resistance gene (P-glycoprotein
gene), the overexpression of which has been detected in drug
resistant cell lines (Lemontt et al., 1988), are located on
chromosome 7 (Human Gene Mapping 9.5, 1988). Elevation
of platelet-derived growth factor (PDGF) A- and B-chain
expression has been detected in human mesothelioma cell
lines (Gerwin et al., 1987; Versnel et al., 1988b). The PDGF
A-chain gene is located on chromosome 7 (Bonthron et al.,
1988) and the PDGF B-chain gene is on chromosome 22
(Human Gene Mapping 9.5, 1988). The PDGF B-chain re-
ceptor has also been shown to be overexpressed in meso-
thelioma cell lines suggesting possible autocrine growth of
mesothelioma cells by this growth factor (Versnel et al.,
1988a). The PDGF receptor has been mapped to chromo-
some 5 (Human Gene Mapping 9.5, 1988).
The various chromosomal abnormalities in our study and
their complex relations may reflect the fact that the tumours
were diagnosed and studied at an advanced stage of their
evolution. The primary chromosomal abnormalities could
have become masked by several secondary changes related to
tumour progression or ageing. However, three patients in this
study had quite simple karyotypic changes: patient no. 16:
48,XX, + 5,+ 7; patient no. 31: 46,XY,t(9;1 1)/+21,t(14 g;17 g)/
t(5;13) (three different clones); and patient no. 36:
50,XY, + X, + Y, + i(5p), + i(5p). Patients nos 6 and 8 also
had simple clones (45,XY,-Y and 47,XY,+Y respectively)
in specimens obtained before treatment from their tumours,
but quite different clones involving complex chromosomal
abnormalities in other specimens obtained also before treat-
ment from the same tumours. It may be possible that in
patients nos 16, 31 and 36, as well as in the patients with
normal karyotypes and/or nonclonal abnormalities, comp-
licated clones were also present but not detected by our
current cytogenetic analysis.
Distinguishing mesothelioma from carcinoma metastatic to
the pleura remains a major problem since there is no specific
stain or test to identify mesothelioma cells and only few
carcinomas have intracellular mucin that is diagnostic to
adenocarcinoma. Several recently described monoclonal
antibodies may facilitate accurate diagnosis (Lee et al., 1986;
Anderson et al., 1987).
The consistent chromosomal abnormalities in
mesothelioma shown in this and in other studies do not, at
present, have diagnositic value. Several other solid tumours
share similar patterns of chromosomal alterations. In a study
of 48 different specimens from solid tumours of 10 different
tissues, especially duplication of chromosome 7 and struc-
tural abnormalities involving chromosomes 1, 3, 7 and 11
were preferentially present in the karyotypic changes (Teys-
sier, 1987). The same abnormalities are also described in
adenocarcinoma of the lung (Rey et al., 1987; Fan & Li,
1987) the pleural metastases of which may be difficult to
distinguish histologically and cytologically from
mesothelioma. Breakpoints at 1p12-p22 are frequently seen
in malignant melanoma (Balaban et al., 1986) and structural
changes of chromosome 1 are common in several tumours
(Brito-Babapulle & Atkin, 1981). Deletions of 3p are specific
abnormalities in small cell carcinomas of the lung (Whang-
Peng et al., 1982) and renal cell carcinomas (Kovacs et al.,
1987). Extra copies of chromosome 7 are frequent in malig-
nant melanoma (Balaban et al., 1986), bladder cancer (Sand-
berg, 1986) and malignant glioma (Bigner et al., 1988).
Monosomy 22 is characteristic to meningioma (Zang, 1982).
Some of the consistent chromosomal abnormalities in
mesothelioma in our study showed a correlation with the
asbestos fibre burden of the corresponding lung. Partial or
total losses of chromosomes I and 4, and translocations and
deletions involving a breakpoint at IpI -p22 correlated with
high content of asbestos fibres in lung tissue. In asbestos-
induced rat mesotheliomas (Libbus & Craighead, 1988) and
in Syrian hamster cell lines transformed by asbestos
(Oshimura et al., 1986) non-random karyotypic changes have
been described. It is not yet demonstrated that asbestos
induces specific chromosome changes in human mesothelial
cells. So far we are aware of only one report of chromosomal
defects in human mesothelial cells exposed to asbestos (Lech-
ner et al., 1985). Losses of chromosomes 11 and 21, dicentric
chromosomes, double minute chromosomes and other
markers were described. It is possible that asbestos fibresCHROMOSOMAL ABNORMALITIES IN MESOTHELIOMA 625
cause chromosomal abnormalities at random sites but that
cells with chromosomal rearrangements in the region
lpll-p22 or losses of chromosomes 1 or 4 have a selective
advantage in tumour progression. The possible relation
between the NRAS oncogene located in lpl3 and/or lp22
and exposure to asbestos remains unknown. It is also
noteworthy that the lpll -p22 region contains several fragile
sites (Human Gene Mapping 9.5, 1988) where breakage
could be induced more easily.
There was a statistically significant correlation between the
number of copies of chromosome 7 p-arms and the prog-
nosis. The more copies of 7p:s that were present in the
tumour cells the shorter was survival. Results of the different
multimodality treatment programs used in our patient series
have been reported elsewhere (Holsti & Mattson, 1988).
None of the therapies was efficient, and there was no
significant difference between the groups. Trisomy 7 (or i(5p))
has been suggested to be associated with increased aggres-
siveness of a tumour in bladder cancer (Sandberg, 1986).
Additionally, extra copies of chromosome 7 p-arms have
been described in advanced malignant melanomas (Balaban et
al., 1986). Chromosome 7 includes several protooncogenes
and growth factor genes the amplification of which could
affect the tumour's behaviour.
In this study no diagnostic marker of mesothelioma was
identified by our cytogenetic analysis. Instead, correlations
between chromosome abnormalities, asbestos exposure and
survival were demonstrated. Further studies are, however,
needed to confirm whether the copy number of chromosome
7 short arms can be considered a prognostic factor in
mesothelioma. When more cytogenetic and molecular genetic
data about mesothelioma accumulate mesothelioma-specific
genetic alterations may be detected and new clinical correla-
tions will be identified.
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